The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Glucose transporters in cancer metabolism
Open accessAbstract
PURPOSE OF REVIEW: Transformed cells exhibit a high rate of glucose consumption beyond that necessary for ATP synthesis. Glucose aids in the generation of biomass and regulates cellular signaling critical for oncogenic progression. A key rate-limiting step in glucose utilization is the transport of glucose across the plasma membrane. This review will highlight key glucose transporters (GLUTs) and current therapies targeting this class of proteins. RECENT FINDINGS: GLUTs, enabling the facilitative entry of glucose into a cell, are increasingly found to be deregulated in cancer. Although cancer-specific expression patterns for GLUTs are being identified, comprehensive analyses substantiating a role for individual GLUTs are still required. Studies defining GLUTs as being rate-limiting in specific tumor contexts, the identification of GLUT1 inhibitors via synthetic lethality screens, novel engagement of the insulin-responsive GLUT4 in myeloma and identification of GLUT9 being a urate transporter, are key advances underscoring the need for continued investigation of this large and enigmatic class of proteins. SUMMARY: Tumor cells exhibit elevated levels of glucose uptake, a phenomenon that has been capitalized upon for the prognostic and diagnostic imaging of a wide range of cancers using radio-labeled glucose analogs. We have, however, not yet been able to target glucose entry in a tumor cell-specific manner for therapy. GLUTs have been identified as rate-limiting in specific tumor contexts. The identification and targeting of tumor-specific GLUTs provide a promising approach to block glucose-regulated metabolism and signaling more comprehensively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Development of a Novel Class of Glucose Transporter Inhibitors
Wang, D.-S., Chu, P., Yang, C., Yan, R., Chuang, Y.-C., Kulp, S. K., & Chen, C. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300015m · Cited by 55
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Otto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Targeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
Macheda, M. L., Rogers, S., & Best, J. D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20166 · Cited by 1,229
Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy
Lee, C., Raffaghello, L., Brandhorst, S., Safdie, F. M., Bianchi, G., Martin-Montalvo, A., Pistoia, V., Wei, M., Hwang, S., Merlino, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003293 · Cited by 715
Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond
Ganapathy, V., Thangaraju, M., & Prasad, P. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.005 · Cited by 710
p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation
Kawauchi, K., Araki, K., Tobiume, K., & Tanaka, N. (2008) · Nature Cell Biology · doi:10.1038/ncb1724 · Cited by 637
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
Chan, D. A., Sutphin, P. D., Nguyen, P., Turcotte, S., Lai, E. W., Banh, A., Reynolds, G. E., Chi, J.-T., Wu, J., Solow-Cordero, D. E., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002394 · Cited by 557
Glucose transporters: expression, regulation and cancer
MEDINA, R. A., & OWEN, G. I. (2002) · Biological Research · doi:10.4067/s0716-97602002000100004 · Cited by 472
The protein family of glucose transport facilitators: It's not only about glucose after all
Augustin, R. (2010) · IUBMB Life · doi:10.1002/iub.315 · Cited by 398
SLC2A9 Is a High-Capacity Urate Transporter in Humans
Caulfield, M. J., Munroe, P. B., O'Neill, D., Witkowska, K., Charchar, F. J., Doblado, M., Evans, S., Eyheramendy, S., Onipinla, A., Howard, P., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050197 · Cited by 378
Expression of GLUT1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers
Krzeslak, A., Wojcik-Krowiranda, K., Forma, E., Jozwiak, P., Romanowicz, H., Bienkiewicz, A., & Brys, M. (2012) · Pathology & Oncology Research · doi:10.1007/s12253-012-9500-5 · Cited by 279
Horn-Ross, P. L. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.5.434 · Cited by 242
GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker
Carvalho, K. C., Cunha, I. W., Rocha, R. M., Ayala, F. R., Cajaíba, M. M., Begnami, M. D., Vilela, R. S., Paiva, G. R., Andrade, R. G., & Soares, F. A. (2011) · Clinics · doi:10.1590/s1807-59322011000600008 · Cited by 229
GLUT1 as a therapeutic target in hepatocellular carcinoma
Amann, T., & Hellerbrand, C. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903307509 · Cited by 204
Marín‐Hernández, A., Rodríguez‐Enríquez, S., Vital‐González, P. A., Flores‐Rodríguez, F. L., Macías‐Silva, M., Sosa‐Garrocho, M., & Moreno‐Sánchez, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05214.x · Cited by 202
A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death
Wood, T. E., Dalili, S., Simpson, C. D., Hurren, R., Mao, X., Saiz, F. S., Gronda, M., Eberhard, Y., Minden, M. D., Bilan, P. J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0569 · Cited by 195
McBrayer, S. K., Cheng, J. C., Singhal, S., Krett, N. L., Rosen, S. T., & Shanmugam, M. (2012) · Blood · doi:10.1182/blood-2011-09-377846 · Cited by 192
Self-citationMathupala, S. P., Ko, Y. H., & Pedersen, P. L. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.03.025 · Cited by 186
Grabellus, F., Nagarajah, J., Bockisch, A., Schmid, K. W., & Sheu, S. (2012) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3182393599 · Cited by 144
Vera, J. C., Reyes, A. M., Cárcamo, J. G., Velásquez, F. V., Rivas, C. I., Zhang, R. H., Strobel, P., Iribarren, R., Scher, H. I., Slebe, J. C., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8719 · Cited by 138
Frolova, A. I., & Moley, K. H. (2011) · Reproduction · doi:10.1530/rep-11-0114 · Cited by 129
Cellular distribution of Glut‐1 and Glut‐5 in benign and malignant human prostate tissue
Reinicke, K., Sotomayor, P. C., Cisterna, P., Delgado, C., Nualart, F., & Godoy, A. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23379 · Cited by 122
Kinetics of transport and phosphorylation of glucose in cancer cells
Rodríguez‐Enríquez, S., Marín‐Hernández, Á., Gallardo‐Pérez, J. C., & Moreno‐Sánchez, R. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21885 · Cited by 111
Direct Inhibition of the Hexose Transporter GLUT1 by Tyrosine Kinase Inhibitors
Vera, J. C., Reyes, A. M., Velásquez, F. V., Rivas, C. I., Zhang, R. H., Strobel, P., Slebe, J. C., Núñez-Alarcón, J. A., & Golde, D. W. (2000) · Biochemistry · doi:10.1021/bi001660j · Cited by 109
Glut1 expression in T1 and T2 stage colorectal carcinomas
Sakashita, M., Aoyama, N., Minami, R., Maekawa, S., Kuroda, K., Shirasaka, D., Ichihara, T., Kuroda, Y., Maeda, S., & Kasuga, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00371-3 · Cited by 107
Velentzis, L. S., Woodside, J. V., Cantwell, M. M., Leathem, A. J., & Keshtgar, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.019 · Cited by 93
Glucose Metabolism as a Target of Histone Deacetylase Inhibitors
Wardell, S. E., Ilkayeva, O., Wieman, H. L., Frigo, D. E., Rathmell, J. C., Newgard, C. B., & McDonnell, D. P. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0179 · Cited by 82
GLUT-1 Expression in Pancreatic Neoplasia: Implications in Pathogenesis, Diagnosis, and Prognosis
Baştürk, O., Singh, R. P., KAYGUSUZ, E. I., Balcı, S., Dursun, N., Çulhacı, N., & Adsay, V. N. (2011) · Pancreas · doi:10.1097/mpa.0b013e318201c935 · Cited by 81
Tarn, C., Skorobogatko, Y. V., Taguchi, T., Eisenberg, B. L., von Mehren, M., & Godwin, A. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3906 · Cited by 78
Novel inhibitors of basal glucose transport as potential anticancer agents
Zhang, W., Liu, Y., Chen, X., & Bergmeier, S. C. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.02.027 · Cited by 78
GLUT7: a new intestinal facilitated hexose transporter
Cheeseman, C. I. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90394.2008 · Cited by 66
Wuest, M., Trayner, B. J., Grant, T. N., Jans, H.-S., Mercer, J. R., Murray, D. L., West, F. G., McEwan, A. J. B., Wuest, F. R., & Cheeseman, C. I. (2011) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2010.11.004 · Cited by 60
Targeting the Warburg effect in hematological malignancies: from PET to therapy
Shanmugam, M., McBrayer, S. K., & Rosen, S. T. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32832f57ec · Cited by 58
Self-citationGlucose Transporter-1 as a New Therapeutic Target in Laryngeal Carcinoma
Luo, X.-M., Zhou, S.-H., & Fan, J. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800601 · Cited by 49
Shanmugam, M., McBrayer, S. K., Qian, J., Raikoff, K., Avram, M. J., Singhal, S., Gandhi, V. V., Schumacker, P. T., Krett, N. L., & Rosen, S. T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000646 · Cited by 42
Self-citationFructose transporter Glut5 expression in clear renal cell carcinoma
Villaamil, M. (2010) · Oncology Reports · doi:10.3892/or.2010.1096 · Cited by 41
Watanabe, M., Naraba, H., Sakyo, T., & Kitagawa, T. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0011 · Cited by 37
Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12
Porpaczy, E. A., Bilban, M., Heinze, G., Gruber, M., Vanura, K., Schwarzinger, I., Stilgenbauer, S., Streubel, B., Fonatsch, C., & Jaeger, U. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02146.x · Cited by 35
Fang, J., Luo, X.-M., Yao, H.-T., Zhou, S.-H., Ruan, L.-X., & Yan, S.-X. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800632 · Cited by 14
Cited by
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?
Hay, N. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.77 · Cited by 1,115
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K
Courtnay, R., Ngo, D. C., Malik, N., Ververis, K., Tortorella, S. M., & Karagiannis, T. C. (2015) · Molecular Biology Reports · doi:10.1007/s11033-015-3858-x · Cited by 567
Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS)
Drew, D., North, R. A., Nagarathinam, K., & Tanabe, M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00983 · Cited by 465
Metadata
- Authors
- Adekola, K., Rosen, S. T., & Shanmugam, M.
- Venue
- Current Opinion in Oncology
- Published
- 2012-11
- Volume
- 24
- Issue
- 6
- Pages
- 650-654
- ISSN
- 1040-8746 (ISSN-L)
- OpenAlex
- W1968963363
- Cited by
- 382
- References
- 41
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.